UC177
(±)-Mephenytoin
Synonym(s):
(±)-5-Ethyl-3-methyl-5-phenyl-2,4-imidazolidinedione, (±)-5-Ethyl-3-methyl-5-phenylhydantoin
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C12H14N2O2
CAS Number:
Molecular Weight:
218.25
UNSPSC Code:
12161501
PubChem Substance ID:
EC Number:
200-012-8
MDL number:
Form:
crystals
Quality level:
form
crystals
Quality Level
color
off-white
mp
115-118 °C, 135-137 °C
solubility
DMSO: soluble
storage temp.
2-8°C
SMILES string
CCC1(NC(=O)N(C)C1=O)c2ccccc2
InChI
1S/C12H14N2O2/c1-3-12(9-7-5-4-6-8-9)10(15)14(2)11(16)13-12/h4-8H,3H2,1-2H3,(H,13,16)
InChI key
GMHKMTDVRCWUDX-UHFFFAOYSA-N
Gene Information
Biochem/physiol Actions
CYP2B6 and CYP2C19 substrate; anticonvulsive, antiepileptic.
Packaging
Bottomless glass bottle. Contents are inside inserted fused cone.
Preparation Note
(±)-Mephenytoin is soluble in DMSO.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
target_organs
Respiratory system
Storage Class
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Gloves
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Related Content
Doaa A Elsherbiny et al.
Journal of pharmacokinetics and pharmacodynamics, 35(2), 203-217 (2008-03-20)
The study aim was to assess the inductive properties of artemisinin antimalarials using mephenytoin as a probe for CYP2B6 and CYP2C19 enzymatic activity. The population pharmacokinetics of S-mephenytoin and its metabolites S-nirvanol and S-4'-hydroxymephenytoin, including enzyme turn-over models for induction
Robert S Foti et al.
Drug metabolism and disposition: the biological fate of chemicals, 36(3), 523-528 (2007-12-01)
Understanding the potential for cytochrome P450 (P450)-mediated drug-drug interactions is a critical part of the drug discovery process. Factors such as nonspecific binding, atypical kinetics, poor effector solubility, and varying ratios of accessory proteins may alter the kinetic behavior of
Robert S Foti et al.
Journal of medicinal chemistry, 55(3), 1205-1214 (2012-01-14)
A series of omeprazole-based analogues was synthesized and assessed for inhibitory activity against CYP2C19. The data was used to build a CYP2C19 inhibition pharmacophore model for the series. The model was employed to design additional analogues with inhibitory potency against